Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals reported positive patient-reported outcomes from the Phase 2 BESTOW trial of investigational tegoprubart in kidney transplant recipients. At 12 months, tegoprubart-treated patients showed mean improvement in symptom occurrence on the MTSOSD-59R scale, while tacrolimus-treated patients had mean worsening; tegoprubart also showed statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale. The excerpt provides no effect sizes or other numerical results.

Analysis

The investable signal is potential differentiation on treatment burden, not proof of a transplant standard-of-care shift. Better patient-reported symptoms could support enrollment, clinician interest, and eventual commercial positioning, but adoption depends on whether tegoprubart can preserve graft outcomes and safety against an entrenched regimen. The release does not provide effect sizes, sample size, statistical details, or comparative rejection, graft-survival, and safety results; verify the full presentation before assigning material value to the PRO findings.

Near term, ELDN may benefit from sentiment and a stronger narrative for further development. Over 1–3 months, the key catalysts are fuller BESTOW data and concrete clinical-development or regulatory updates. Over 6–18 months, the thesis requires confirmatory evidence that symptom benefits coexist with acceptable rejection, infection, and graft outcomes. Tacrolimus’s established role creates a high evidence bar; symptom improvement alone is unlikely to displace it. The contrarian angle is that patient burden can matter commercially even without immediate hard-endpoint superiority, but this release alone does not establish willingness to switch or pay.

Key Decisions for Investors

• Treat the release as a modest positive catalyst, not a basis for extrapolating commercial value. Avoid chasing an event-driven spike until the full dataset clarifies effect size, patient numbers, statistical significance, and missing clinical endpoints.
• Keep ELDN on a catalyst watchlist rather than making a high-conviction directional trade from this disclosure alone. Reassess after the next trial update, focusing on rejection, graft function/survival, infection, discontinuation, and whether symptom differences are clinically meaningful.
• Falsify the differentiation thesis if subsequent data show no durable PRO benefit, worse graft or safety outcomes, or development delays that weaken the path to a confirmatory study. A sharp price move unsupported by new hard-endpoint evidence would also argue against chasing.